Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a single-center, open-label study to assess how probenecid affects the pharmacokinetics of mirdametinib and its metabolites in healthy adult participants. The study aims to evaluate the changes in drug concentrations when both drugs are taken together, providing important information on drug interactions. The trial is sponsored by Merck Healthcare KGaA, Darmstadt, Germany, and includes healthy volunteers aged 18 to 65 years. Participants will receive oral mirdametinib capsules alone and in combination with oral probenecid tablets during two sequential periods within the study. The total study time for each participant is about 56 days, including a 28-day screening phase, a 19-day assessment phase covering both treatment periods, and a follow-up visit about 7 days after leaving the clinical research unit. The study is designed to observe how the presence of probenecid influences the levels of mirdametinib and its metabolites in the body. During the study, participants will undergo various medical evaluations including clinical chemistry, blood tests, urine tests, vital signs monitoring, ECGs, ophthalmic exams, and physical assessments. Blood samples will be collected to measure drug concentrations over the course of the treatment periods. Safety will be monitored by tracking adverse events and clinical laboratory findings. The entire participation duration is approximately 56 days, with close observation throughout the screening, treatment, and follow-up phases.
Actively Recruiting
This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the safety and immune response of a new vaccine candidate called LTB-NG6, designed to prevent Neisseria gonorrhoeae infection. The study focuses on healthy adults aged 18 to 50 years and is a phase 1 trial to assess initial safety and immune reactions. Participants are randomly assigned to receive either one of five different doses of the vaccine or a placebo. Participants will receive two doses of either the investigational vaccine at varying dose levels or a placebo consisting of sodium chloride 0.9%. The vaccine includes six different Neisseria gonorrhoeae antigens and is administered in a two-dose schedule. The study is conducted using a double-blind design, meaning neither participants nor researchers know who receives which treatment during the trial. During the study, participants will be monitored for local and systemic adverse events for seven days after each injection and for any other events for 28 days post-injection. Unsolicited adverse events will be followed throughout the study, which lasts around 18 months on average. Immune responses will be measured by antibody levels 28 days after the second injection, with additional examinations of safety and lab tests at baseline and after each dose. Participants will also complete diary forms and attend follow-up visits and phone calls throughout the trial.